RR
Rubicon Research
Book Building issueMainboardNSE₹1,378 Cr issue
+27.86%
Listing gain over issue price
Issue size
₹1,378 Cr
1 lot at cut-off
₹14,550
Lot size
30shares
Open
09 Oct 2025
Close
13 Oct 2025
Allotment
14 Oct 2025
Listing
16 Oct 2025
Listing performance
Issue price
₹485
Listed at
₹620.10
Listing-day close
₹628.20
Latest price
₹1,374.20
Listing gain
+27.86%
Return since listing
+183.34%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Grey market premium
Unofficial and indicative — not a forecast
₹120
3 observations recorded — too few to plot a trend.
Day-wise premium · 3 observations
| Date | GMP | % | Sauda | Est. listing | Gain / lot |
|---|---|---|---|---|---|
| 16 Oct 2025 | ₹120 | +24.74% | ₹2,700 | ₹605 | ₹3,600 |
| 15 Oct 2025 | ₹151 | +31.13% | ₹3,400 | ₹636 | ₹4,530 |
| 14 Oct 2025 | ₹128 | +26.39% | ₹2,900 | ₹613 | ₹3,840 |
Gain per lot assumes the premium holds to listing and that the application is allotted — allotment in an oversubscribed issue is a lottery, so it is indicative, not expected. Sauda is the rate paid for a submitted application itself.
Issue details
- IPO date
- 09 Oct 2025 – 13 Oct 2025
- Listing date
- 16 Oct 2025
- Face value
- ₹1 per share
- Issue price
- ₹485 per share
- Lot size
- 30 shares
- Issue type
- Book Building issue
- Listing at
- NSE
- Total issue size
- ₹1,378 Cr
- Market cap at offer price
- ₹7,990 Cr
- Promoter holding
- 75.71% → 59.78% pre-issue → post-issue
- ISIN
- INE506V01022
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead managers
- Axis Capital Ltd.
- Registered office
- MedOne House, B-75, Road No.33, Wagle Estate, Maharashtra
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 1,27,64,691 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 30 shares per lot, in multiples, at ₹485
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 30 | ₹14,550 |
| Retail (max) | 13 | 390 | ₹1,89,150 |
| S-HNI (min) | 14 | 420 | ₹2,03,700 |
| S-HNI (max) | 68 | 2,040 | ₹9,89,400 |
| B-HNI (min) | 69 | 2,070 | ₹10,03,950 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
1,27,64,691
Anchor portion
₹619 Cr
at ₹485 per share
Valuation and performance
Valuation at offer price
₹485 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 8.70 | 10.51 |
| P/E (×) | 55.75 | 46.15 |
| Price to book (×) | 13.65 | — |
| Market cap | — | ₹7,990 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 29.02%
- ROCE
- 26.45%
- Debt / equity
- 0.73
- PAT margin
- 10.37%
- EBITDA margin
- 20.67%
- NAV per share
- ₹35.53
- Price to book
- 13.65
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Rubicon Research
Rubicon Research Limited (formerly Rubicon Research Private Limited) was incorporated on May 6, 1999, and converted to a public limited company in 2024. The company is a pharmaceutical formulations company driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly the United States. As of June 30, 2025, the company has a portfolio of 72 active ANDA and nine NDA products approved by the USFDA, with 17 new products awaiting USFDA ANDA approval and 63 product candidates in development. The company sells branded and non-branded pharmaceutical products, deriving 95.05% and 4.95% of revenue from sale of goods from non-branded and branded products respectively for the three months ended June 30, 2025.
Company Analysis
from RHPRubicon Research Limited is a pharmaceutical formulations company focused on specialty products and drug-device combinations for regulated markets, particularly the United States.
Rubicon Research Limited (formerly Rubicon Research Private Limited) was incorporated on May 6, 1999, and converted to a public limited company in 2024. The company is a pharmaceutical formulations company driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly the United States. As of June 30, 2025, the company has a portfolio of 72 active ANDA and nine NDA products approved by the USFDA, with 17 new products awaiting USFDA ANDA approval and 63 product candidates in development. The company sells branded and non-branded pharmaceutical products, deriving 95.05% and 4.95% of revenue from sale of goods from non-branded and branded products respectively for the three months ended June 30, 2025.
pharmaceutical formulationsspecialty pharmaceuticalsgeneric drugsregulated markets
Objects of the Issue
- Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our Company ₹3,100 million p.27
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes p.27
- Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our Company ₹3,100 million p.145
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes p.145
- Repayment of certain outstanding borrowings availed by our Company p.150
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives and general corporate purposes p.150
- General corporate purposes p.152
- Not disclosed in Part 5 of document
- Not disclosed in Part 9 - Objects of the Offer section not included in this document portion
Issue Structure
- Total Issue
- Up to ₹13,774.99 million
- Fresh Issue
- Up to ₹5,000 million
- Offer for Sale
- Up to ₹8,774.99 million
- Price Band
- [●] (to be determined)
- Lot Size
- [●] (to be determined)
- Face Value
- ₹1 each
Business Model
The company earns revenue from the sale of pharmaceutical products, including generic (non-branded) and branded formulations. For the three months ended June 30, 2025, the company derived 99.50% of revenue from operations from the United States. The company operates through its wholly-owned subsidiaries AdvaGen Pharma Ltd. and Validus Pharmaceuticals LLC for undertaking sales in the United States, and also relies on wholesale distributors including major customers.
Business Segments
Products in the analgesics and pain management therapy area
Cardiovascular products
Central nervous system products
Hypokalemia products
Skeletal muscle relaxant products
Manufactures oral solid dosages at Ambernath facility
Manufactures unit-dose, bi-dose, and multi-dose nasal sprays at Ambernath facility
Manufactures oral liquid dosages at Satara facility
Manufactures oral solid dosages for steroids, hormones and high-potency products, and topical ointments at Pithampur facility
The company undertakes research and development activities in pharmaceutical research laboratories with contracts from pharmaceutical industry customers
The company acquires, reformulates and markets FDA-approved prescription products through Validus subsidiary
Development and commercialization of specialty pharmaceutical products with limited generic competition, including CNS, CVS, and other therapeutic areas
Development of complex formulations and new ANDA applications; as of June 30, 2025, the company had 170 scientists in R&D teams based in India and Canada focused on formulations development and commercialization, with 72 active ANDAs and 17 new applications under FDA review
Marketing and promotion of branded specialty products in CNS and CVS therapy areas in the US market, with distribution network in 44 of 50 US states and portfolio of 10 products including Equetro® and Lopressor®
Manufacturing, packaging, and storage of pharmaceutical products at facilities in Satara, Maharashtra (oral liquids) and Pithampur, Madhya Pradesh (steroids, hormones, high-potency products, and topical ointments)
Includes analgesics for pain management, CNS therapeutic products targeting depression, anxiety, schizophrenia, epilepsy, Parkinson's disease, Alzheimer's disease. Key products include Baclofen (spasticity treatment), Carbidopa-Levodopa (Parkinson's disease), Diclofenac Potassium (pain/anti-inflammatory), Tramadol Hydrochloride (opioid analgesic), Cyclobenzaprine Hydrochloride (muscle relaxant), and branded specialty products Equetro and Raldesy.
Products for cardiovascular disease treatment including beta-blockers and other cardiac medications. Key products include Metoprolol Tartrate (beta-blocker for hypertension, angina, heart failure) with 37.3% market share in FY2025.
Non-narcotic and opioid analgesic products for chronic pain, acute pain, post-surgical pain management and pain related to various conditions.
Including Hypokalemia products (potassium supplementation), Skeletal Muscle Relaxants, Nicotine Replacement Therapy (NRT), Gastrointestinal products, Metabolic products, Immunosuppressant products, and others
Products with no competitors or one competitor for at least one year from commercial launch date, and branded specialty CNS products marketed through subsidiary Validus including Equetro (carbamazepine) and Raldesy (trazodone hydrochloride oral solution).
Development and manufacturing of generic pharmaceutical formulations across oral solids, oral liquids, injectables, ophthalmic, and topicals for the US and international markets
R&D and formulation of nasal and inhalation products such as nasal sprays, dry powder inhalers, metered dose inhalers
Commercialization and promotion of branded specialty products in CNS and CVS therapy areas through Validus Pharmaceuticals LLC
Research, development and production of pharmaceutical products; contract research services for pharma industry customers; sale of generic medicines and healthcare products; drug-device combination products; third-party logistics services
Manufacture and sale of generic pharmaceutical products, specialty pharmaceuticals, and APIs
Income from research services including sale of technology/know-how (rights, licenses and other intangibles)
Export benefits and other incentives from government schemes
Royalty income from licensing arrangements
Pain management therapy area products
Central nervous system therapy area products
Cardiovascular therapy area products
Products with no competitors or one competitor for at least one year from commercial launch date, including branded products through Validus
Oral solid pharmaceutical formulations manufactured at Ambernath facility
Oral liquid formulations including syrups, suspensions and solutions manufactured at Satara facility
Nasal spray formulations including unit-dose, bi-dose and multi-dose products
Hypokalemia therapy area products
SWOT Analysis
Strengths
- • Complete focus on regulated markets among Indian pharma peers(p.26)
- • Substantial approved product portfolio in US market(p.26)
- • Significant pipeline of products in development(p.26)
- • Strong revenue growth trajectory(p.29)
- • Achieved profitability with positive earnings(p.40)
- • Diversified product portfolio across therapy areas(p.26)
- • Validus acquisition enables independent US commercialization(p.100)
- • Substantial export operations and global market presence(p.89)
- • Strong revenue growth trajectory(p.102)
- • Exclusive focused specialization on US regulated markets among Indian peers(p.249)
- • Exceptional revenue growth significantly outpacing peers(p.249)
- • Diversified commercialized product portfolio with market leadership in key products(p.249)
- • Strong price resilience vs. industry average erosion(p.254)
- • High commercialization rate enabling better ROI monetization(p.254)
- • Clean regulatory compliance record with no OAI status(p.249)
- • R&D investment nearly double industry peer average(p.252)
- • Specialized expertise in complex drug-device combination nasal sprays(p.261)
- • Extensive R&D infrastructure with DSIR-approved facility and FDA-inspected centers(p.272)
- • Significant portfolio of approved and pipeline products for FDA markets(p.272)
- • Skilled and dedicated workforce in R&D and quality functions(p.272)
- • Strong quality management systems and compliance infrastructure(p.272)
- • US FDA approvals demonstrating manufacturing excellence(p.272)
- • Validated IT systems and cloud infrastructure for business continuity(p.275)
- • Comprehensive patent and trademark portfolio for IP protection(p.276)
- • Experienced leadership with pharmaceutical sector background(p.323)
- • Integrated pharmaceutical company with full value chain capabilities(p.364)
- • GMP-certified manufacturing facilities(p.364)
- • Strong financial backing from institutional investor(p.345)
- • Fastest-growing Indian pharmaceutical formulations company among peers(p.427)
- • Only Indian pharmaceutical player with complete focus on regulated markets(p.427)
- • Strong ANDA approval track record and portfolio diversity(p.427)
- • Significant market share leadership in multiple products(p.427)
- • Clean regulatory inspection record with no OAI status since 2013(p.427)
- • Growing specialty products portfolio with high margins(p.432)
- • Strong R&D investment and capability relative to peers(p.430)
- • Price resilience despite industry-wide erosion(p.436)
Weaknesses
- • Severe dependence on US market revenue(p.35)
- • High concentration among top five customers(p.40)
- • History of losses and negative returns in prior year(p.40)
- • High working capital requirements(p.41)
- • Significant capital expenditure needs(p.41)
- • Product recalls and regulatory compliance issues(p.38)
- • Manufacturing facilities concentrated across only three locations with certain products produced by single facility(p.44)
- • Very low capacity utilization rates across manufacturing facilities(p.46)
- • Heavy dependence on top suppliers for raw materials(p.53)
- • High concentration of revenue in USA market with exposure to foreign currency risk(p.47)
- • Negative unhedged foreign currency exposures(p.48)
- • History of covenant defaults requiring waivers from lenders(p.52)
- • Validus acquisition with goodwill exceeding purchase price and ongoing operating losses(p.51)
- • Certain subsidiaries have incurred losses in the past(p.72)
- • Corporate Promoter lacks experience in pharmaceutical business(p.61)
- • Untraceable corporate records and missing statutory filings(p.60)
- • Significant dependence on pharmaceutical sector customers(p.89)
- • High debt obligations requiring scheduled repayment(p.146)
- • Certain directors lack listed company board experience(p.88)
- • Corporate records not traceable; potential regulatory exposure(p.135)
- • Small scale relative to major global competitors(p.240)
- • Significant concentration in top customer revenue(p.269)
- • Limited diversification beyond US market(p.249)
- • Reliance on limited manufacturing facilities post-acquisition integration(p.257)
- • Moderate gross margins with competitive pressure(p.254)
- • Small scale and resource constraints relative to backward-integrated competitors(p.276)
- • Significant exposure to currency fluctuations through US operations and imports(p.297)
- • Insurance coverage may be insufficient for all operational hazards(p.275)
- • Leasehold tenure on key manufacturing facilities creates long-term uncertainty(p.277)
- • Dependence on key personnel(p.323)
- • Limited independent director representation(p.328)
- • Significant capital work-in-progress requiring continued investment(p.372)
- • High inventory levels and increasing working capital requirements(p.451)
- • Significant dependence on few major customers for revenue(p.459)
- • Heavy concentration of revenue in top products(p.428)
- • Significant debt obligations and leverage(p.462)
- • High ongoing capital expenditure requirements(p.455)
- • Pending patent and product infringement litigation(p.468)
Opportunities
- • US market dominance and growth potential(p.26)
- • Significant pipeline for future product launches(p.26)
- • Expansion through acquisitions and strategic initiatives(p.27)
- • Debt reduction to improve financial flexibility(p.27)
- • Expansion of manufacturing capabilities through strategic acquisitions(p.50)
- • Growth in specialty products and drug-device combinations(p.50)
- • Expansion into regulated markets beyond USA(p.50)
- • Debt reduction to improve leverage and future capital access(p.147)
- • Inorganic growth through unidentified acquisitions(p.145)
- • Public listing benefits for brand enhancement and market access(p.145)
- • Large upcoming patent cliff opportunities in CNS and CVS therapy areas(p.261)
- • High-growth nasal spray segment with specialized positioning(p.261)
- • Expansion into similarly regulated markets leveraging US approvals(p.262)
- • Addressing persistent US drug shortages with reliable supply(p.209)
- • Growing injectables market segment with 2x oral solids growth rate(p.210)
- • Co-development and licensing partnerships for specialty products(p.262)
- • Branded specialty product expansion through Validus platform(p.261)
- • Acquisition of complementary manufacturing capabilities and facilities(p.262)
- • Expand branded specialty product commercialization through Validus platform(p.274)
- • Grow US distribution network and market presence(p.274)
- • Leverage new manufacturing capabilities for high-potency products(p.274)
- • Scale nasal and inhalation product development and manufacturing(p.272)
- • Continue ANDA approvals to grow generic product portfolio(p.276)
- • Reduce environmental impact and operational costs through renewable energy(p.274)
- • Expansion of R&D capabilities and product portfolio(p.323)
- • International expansion through existing subsidiaries(p.364)
- • Consumer healthcare product development(p.364)
- • Expansion of specialty products portfolio with higher margins(p.432)
- • Expansion of dosage form capabilities to address new market segments(p.432)
- • Growth from new product launches and pipeline(p.431)
- • Expansion of manufacturing capacity in high-potency segment(p.432)
- • Growth in nasal spray product category(p.433)
- • Increasing market opportunity in regulated pharmaceutical markets(p.427)
- • Strategic partnerships and co-development opportunities(p.438)
Threats
- • US tariff implementation on branded pharmaceutical products(p.37)
- • Regulatory inspection risks and facility closure potential(p.38)
- • Healthcare reform and pricing pressures(p.36)
- • Dependence on third-party contract manufacturers(p.43)
- • R&D investment inefficacy risk(p.41)
- • Foreign currency exposure risks(p.30)
- • Risk of manufacturing disruptions from regulatory inspections and facility closures(p.44)
- • Supply chain disruptions from natural/man-made disasters and external factors(p.44)
- • Intense competition from other pharmaceutical manufacturers(p.55)
- • Competitors may develop products more competitive than ours(p.56)
- • Consolidation in healthcare value chain increasing buyer power(p.59)
- • Healthcare reform and price regulation initiatives(p.68)
- • Medicare Part D price negotiation and rebate programs(p.68)
- • Foreign exchange rate volatility and potential rupee depreciation(p.48)
- • Regulatory compliance burden and potential product recalls(p.44)
- • Energy cost inflation and electricity supply disruptions(p.70)
- • Leasehold property tenure limitations for key facilities(p.58)
- • Pharmaceutical sector downturns directly impact demand(p.89)
- • Export duties and trade barriers in destination countries(p.89)
- • Changing pharmaceutical regulations and compliance uncertainty(p.89)
- • Global geopolitical and supply chain disruptions(p.91)
- • Indian economic and political instability affecting operations(p.90)
- • Post-IPO surveillance measures and trading restrictions(p.89)
- • Intense generic price erosion and competitive dynamics(p.254)
- • Customer consolidation and bargaining power concentration(p.230)
- • Regulatory compliance complexity and FDA inspection risks(p.231)
- • Supply chain vulnerability and drug shortage cascades(p.233)
- • Reimbursement pressure and government price controls(p.233)
- • Market saturation in mature generic segments(p.233)
- • Intense competition from established pharmaceutical manufacturers with greater resources(p.276)
- • Regulatory pricing controls and price negotiations by government and payers(p.278)
- • Complex and evolving US healthcare fraud and abuse laws affecting marketing(p.291)
- • Medicare pricing negotiation and inflation rebate requirements reducing revenues(p.294)
- • Mandatory Medicaid rebates capping profitability on covered outpatient drugs(p.293)
- • Ongoing product patent litigation and market exclusivity challenges(p.290)
- • Exposure to hazardous manufacturing operations and environmental compliance risks(p.275)
- • Exposure to foreign exchange fluctuations through international operations(p.361)
- • Regulatory compliance requirements across multiple jurisdictions(p.364)
- • Pharmaceutical industry competition and pricing pressures(p.364)
- • Regulatory pricing pressures from IRA and government price negotiations(p.436)
- • Emerging MFN pricing requirements that could mandate reduced prices(p.436)
- • Tariffs on branded pharmaceutical products manufactured outside the US(p.460)
- • Intense competition from larger pharmaceutical manufacturers(p.438)
- • Ongoing generic price erosion in the market(p.436)
- • Customer consolidation increasing buyer power(p.438)
- • Dependence on third-party suppliers and manufacturers(p.435)
- • Complex regulatory compliance requirements and inspection risks(p.437)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| General Atlantic Singapore RR Pte. Ltd. | Corporate Promoter / Promoter Selling Shareholder | 52.15% | — |
| Pratibha Pilgaonkar | Individual Promoter | 4.15% | — |
| Sudhir Dhirendra Pilgaonkar | Individual Promoter | 4.15% | — |
| Parag Suganchand Sancheti | Individual Promoter | 0.02% | — |
| Surabhi Parag Sancheti | Individual Promoter | 8.45% | — |
| Sumant Sudhir Pilgaonkar | Individual Promoter | 8.43% | — |
| General Atlantic Singapore RR Pte. Ltd. (Corporate Promoter) | Promoter | 52.15% | — |
| General Atlantic Singapore RR Pte. Ltd. | Promoter/Selling Shareholder | 52.15% | — |
| Pratibha Pilgaonkar | Promoter | 4.15% | — |
| Sudhir Dhirendra Pilgaonkar | Promoter | 4.15% | — |
| Surabhi Parag Sancheti | Promoter | 8.45% | — |
| Sumant Sudhir Pilgaonkar | Promoter | 8.43% | — |
| Parag Suganchand Sancheti | Promoter | 0.02% | — |
| General Atlantic Singapore RR Pte. Ltd. | Promoter | — | — |
| General Atlantic Singapore RR Pte. Ltd. | Corporate Promoter / Majority Shareholder | — | — |
| General Atlantic Singapore RR Pte. Ltd. | Promoter | — | — |
| General Atlantic Singapore RR Pte. Ltd. | Corporate Promoter | 77.34% (on fully diluted basis as of RHP date) | — |
| Pratibha Pilgaonkar | Individual Promoter | 4.15% (on fully diluted basis); 6,435,000 equity shares | [●] |
| Sudhir Dhirendra Pilgaonkar | Individual Promoter | 4.15% (on fully diluted basis); 6,435,000 equity shares | [●] |
| Parag Suganchand Sancheti | Individual Promoter | 0.02% (on fully diluted basis); 30,000 equity shares | [●] |
| Surabhi Parag Sancheti | Individual Promoter | 8.45% (on fully diluted basis); 13,095,000 equity shares | [●] |
| Sumant Sudhir Pilgaonkar | Individual Promoter | 8.43% (on fully diluted basis); 13,065,000 equity shares | [●] |
| General Atlantic Singapore RR PTE LTD | Holding Company/Promoter Group | 58.44% | 57.67% |
| Sudhir Dhirendra Pilgaonkar | Promoter | 4.23% | 4.18% |
| Pratibha Sudhir Pilgaonkar | Promoter | 4.23% | 4.18% |
| Surabhi Sancheti | Promoter | 8.61% | 8.50% |
| Sumant Pilgaonkar | Promoter | 8.59% | 8.48% |
| Parag Sancheti | Promoter | 0.02% | 0.02% |
| General Atlantic Singapore RR Pte. Ltd. | Promoter Selling Shareholder | — | — |
| General Atlantic Singapore RR Pte. Ltd. | Promoter Selling Shareholder / Investor | — | — |
| Parag Suganchand Sancheti | Management Shareholder | — | — |
| Pratibha Sudhir Pilgaonkar | Management Shareholder | — | — |
Leadership
Pratibha Pilgaonkar · Managing Director
Parag Suganchand Sancheti · CEO
Nitin Jajodia · CFO
Deepashree Tanksale · Company Secretary and Compliance Officer
Venkat Changavalli · Chairman and Independent Director
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.